BioCentury
ARTICLE | Company News

AbbVie gains option to Teneobio BCMA program

February 13, 2019 11:21 PM UTC

AbbVie Inc. (NYSE:ABBV) will pay $90 million up front for an option to acquire bispecific antibody TNB-383B from Teneobio Inc. (Menlo Park, Calif.), which would give AbbVie its first BCMA-targeted asset.

TNB-383B targets BCMA and CD3 and is in preclinical testing to treat multiple myeloma. CBO Omid Vafa told BioCentury that TNB-383B uses Teneobio's T cell engager platform, which combines a heavy chain-only anti-BCMA binder with a novel anti-CD3 binder to decouple target cancer cell killing from cytokine release. Vafa said the company believes TNB-383B will offer a better therapeutic window over competing bispecifics...